Australia's F H Faulding is planning to buy out the minority interestsin its 71%-owned US subsidiary Faulding Inc, for $13.50 per share, or about $79 million. The deal is subject to approval by minority holders in the US unit, a meeting of whom is scheduled for mid-December.
The acquisition will be funded in part by a one-for-eight rights issue, which will raise A$107 million ($76.9 million). The issue will be pitched at A$6.80 per share and would result in the issue of 15.7 million shares, which would not rank for the 1997 final dividend, according to Reuters. The transaction is being structured as a reverse stock split in which Faulding Inc shareholders, other than F H Faulding, would receive cash for all their shares.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze